Brief: Lee's Pharmaceutical Says Fondaparinux Sodium Injection Got Approval For Drug Registration From China's NMPA
05/02/2021 14:34
Feb 5 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* FONDAPARINUX SODIUM INJECTION OBTAINED APPROVAL FOR DRUG
REGISTRATION FROM NMPA OF PRC
Source text for Eikon: ID:nHKS8DsYFr
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals